Status:
COMPLETED
Observational Study of Lumigan® 0.01% Treatment for Patients With Primary Open Angle Glaucoma or Ocular Hypertension
Lead Sponsor:
Allergan
Conditions:
Glaucoma, Open-Angle
Ocular Hypertension
Eligibility:
All Genders
18+ years
Brief Summary
This study will assess the efficacy, safety, tolerability and persistence of use of Lumigan ® 0.01% in patients diagnosed with primary open-angle glaucoma or ocular hypertension who are treated per ro...
Eligibility Criteria
Inclusion
- Diagnosis of primary open-angle glaucoma or ocular hypertension
- Lumigan® 0.01% prescribed either as monotherapy or adjunctive to beta-blocker therapy
Exclusion
- None
Key Trial Info
Start Date :
September 1 2011
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 1 2013
Estimated Enrollment :
387 Patients enrolled
Trial Details
Trial ID
NCT01489670
Start Date
September 1 2011
End Date
March 1 2013
Last Update
March 28 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Bülach, Canton of Zurich, Switzerland